12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-SMNRx: Phase II started

Isis began an open-label, dose-escalation, North American Phase II trial to evaluate 3 intrathecal injections of ISIS-SMNRx in 8 infants with SMA ages 3 weeks to 7 months. Dosing of the first patient in the trial...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >